Skip to main content
Premium Trial:

Request an Annual Quote

Tempus, Bristol Myers Squibb Expand Cancer Biomarker Alliance

NEW YORK — Tempus said on Wednesday that its cancer biomarker alliance with Bristol Myers Squibb has been expanded to include RNA-based targets.

According to Tempus, it has been providing Bristol Myers Squibb with de-identified transcriptomic datasets to help in the identification of new biomarkers related to undisclosed cancer subtypes. Under the expanded deal, Bristol Myers Squibb has licensed from Tempus terabytes of additional data cohorts across multiple tumor types, which will be analyzed with a focus on RNA expression targets.

Additional terms were not disclosed.

"Our work with Bristol Myers Squibb has made it possible to transform terabytes of data into clinically relevant insight by stratifying diseases into key molecular subtypes and uncovering potentially better ways to treat patients going forward," Tempus Chief Operating Officer Ryan Fukushima said in a statement.

In December, Chicago-based Tempus raised $200 million in a new Series G2 financing round and announced an oncology testing alliance with Bayer.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.